Molecular Biology and Genetics of Lung Cancer

  • Neil E. Martin
  • Stephen M. Hahn
  • W. Gillies McKenna
Part of the Medical Radiology Radiation Oncology book series (MEDRAD)


Lung Cancer Clin Oncol Small Cell Lung Cancer Radiation Resistance Small Cell Lung Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adjei AA, Mauer A, Bruzek L et al (2003) Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 21:1760–1766CrossRefPubMedGoogle Scholar
  2. Beier R, Burgin A, Kiermaier A et al (2000) Induction of cyclin E-cdk2 kinase activity, E2F-dependent transcription and cell growth by Myc are genetically separable events. EMBO J 19:5813–5823CrossRefPubMedGoogle Scholar
  3. Bergqvist M, Brattstrom D, Gullbo J et al (2003) p53 status and its in vitro relationship to radiosensitivity and chemosensitivity in lung cancer. Anticancer Res 23:1207–1212PubMedGoogle Scholar
  4. Brunner TB, Hahn SM, Gupta AK et al (2003) Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res 63:5656–5668PubMedGoogle Scholar
  5. Cohen-Jonathan E, Muschel RJ, McKenna WG et al (2000) Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat Res 154:125–132PubMedGoogle Scholar
  6. Crick FH (1958) On protein synthesis. Symp Soc Exp Biol 12:138–163PubMedGoogle Scholar
  7. Gao N, Hu YD, Cao XY et al (2001) The exogenous wild-type p14ARF gene induces growth arrest and promotes radio-sensitivity in human lung cancer cell lines. J Cancer Res Clin Oncol 127:359–367CrossRefPubMedGoogle Scholar
  8. Gazzeri S, Brambilla E, Caron de Fromentel C et al (1994) p53 genetic abnormalities and myc activation in human lung carcinoma. Int J Cancer 58:24–32PubMedGoogle Scholar
  9. Gorski DH, Beckett MA, Jaskowiak NT et al (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374–3378PubMedGoogle Scholar
  10. Graziano SL, Gamble GP, Newman NB et al (1999) Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 17:668–675PubMedGoogle Scholar
  11. Gupta AK, McKenna WG, Weber CN et al (2002) Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 8:885–892PubMedGoogle Scholar
  12. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70CrossRefPubMedGoogle Scholar
  13. Heasley LE (2001) Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene 20:1563–1569PubMedGoogle Scholar
  14. Henriksson M, Luscher B (1996) Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res 68:109–182PubMedGoogle Scholar
  15. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042–2054PubMedGoogle Scholar
  16. Hiyama K, Hiyama E, Ishioka S et al (1995) Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 87:895–902PubMedGoogle Scholar
  17. Huncharek M, Muscat J, Geschwind JF (1999) K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 20:1507–1510CrossRefPubMedGoogle Scholar
  18. Johnson BE, Fischer T, Fischer B et al (2003) Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 9:5880–5887PubMedGoogle Scholar
  19. Johnson DH, DeVore R, Kabbinavar F et al (2001) Carboplatin (C) + Paclitaxel (T) + RhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proc Am Soc Clin Oncol 20:1256aGoogle Scholar
  20. Kaye FJ (2002) RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene 21:6908–6914CrossRefPubMedGoogle Scholar
  21. Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823PubMedGoogle Scholar
  22. Kraus AC, Ferber I, Bachmann SO et al (2002) In vitro chemo-and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 21:8683–8695CrossRefPubMedGoogle Scholar
  23. Kris MG, Natale RB, Herbst RS et al (2002) A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 21:2929aGoogle Scholar
  24. Kroemer G (1997) The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 3:614–620CrossRefPubMedGoogle Scholar
  25. Krystal G, Birrer M, Way J et al (1988) Multiple mechanisms for transcriptional regulation of the myc gene family in small-cell lung cancer. Mol Cell Biol 8:3373–3381PubMedGoogle Scholar
  26. Lander ES, Linton LM, Birren B et al (2001) Initial sequencing and analysis of the human genome. Nature 409:860–921CrossRefPubMedGoogle Scholar
  27. Lantuejoul S, Moro D, Michalides RJ et al (1998) Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors. Am J Surg Pathol 22:1267–1276CrossRefPubMedGoogle Scholar
  28. Laskey RA, Earnshaw WC (1980) Nucleosome assembly. Nature 286:763–767CrossRefPubMedGoogle Scholar
  29. Lebowitz PF, Prendergast GC (1998) Non-Ras targets of farne-syltransferase inhibitors: focus on Rho. Oncogene 17:1439–1445CrossRefPubMedGoogle Scholar
  30. Lucchi M, Mussi A, Fontanini G et al (2002) Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg 21:1105–1110CrossRefPubMedGoogle Scholar
  31. Macaulay VM, Salisbury AJ, Bohula EA et al (2001) Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radio-sensitivity and impaired activation of Atm kinase. Oncogene 20:4029–4040CrossRefPubMedGoogle Scholar
  32. Martin B, Paesmans M, Berghmans T et al (2003) Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 89:55–64CrossRefPubMedGoogle Scholar
  33. McKenna WG, Weiss MC, Endlich B et al (1990) Synergistic effect of the v-myc oncogene with H-ras on radioresistance. Cancer Res 50:97–102PubMedGoogle Scholar
  34. Meert AP, Martin B, Delmotte P et al (2002) The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 20:975–981CrossRefPubMedGoogle Scholar
  35. Meert AP, Martin B, Paesmans M et al (2003) The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer 89:959–965CrossRefPubMedGoogle Scholar
  36. Misawa M, Tauchi T, Sashida G et al (2002) Inhibition of human telomerase enhances the effect of chemotherapeutic agents in lung cancer cells. Int J Oncol 21:1087–1092PubMedGoogle Scholar
  37. Mitsudomi T, Hamajima N, Ogawa M et al (2000) Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6:4055–4063PubMedGoogle Scholar
  38. Moriya Y, Niki T, Yamada T et al (2001) Increased expression of laminin-5 and its prognostic significance in lung adenocarcinomas of small size. An immunohistochemical analysis of 102 cases. Cancer 91:1129–1141CrossRefPubMedGoogle Scholar
  39. Olivier M, Eeles R, Hollstein M et al (2002) The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19:607–614CrossRefPubMedGoogle Scholar
  40. Osada H, Takahashi T (2002) Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene 21:7421–7434CrossRefPubMedGoogle Scholar
  41. Pietras RJ, Poen JC, Gallardo D et al (1999) Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347–1355PubMedGoogle Scholar
  42. Potti A, Willardson J, Forseen C et al (2002) Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. Lung Cancer 36:257–261CrossRefPubMedGoogle Scholar
  43. Protopopov AI, Li J, Winberg G et al (2002) Human cell lines engineered for tetracycline-regulated expression of tumor suppressor candidate genes from a frequently affected chromosomal region, 3p21. J Gene Med 4:397–406CrossRefPubMedGoogle Scholar
  44. Robles AI, Linke SP, Harris CC (2002) The p53 network in lung carcinogenesis. Oncogene 21:6898–6907CrossRefPubMedGoogle Scholar
  45. Rodenhuis S, Slebos RJ (1992) Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52:2665s–2669sPubMedGoogle Scholar
  46. Ronen A, Glickman BW (2001) Human DNA repair genes. Environ Mol Mutagen 37:241–283CrossRefPubMedGoogle Scholar
  47. Santoni-Rugiu E, Falck J, Mailand N et al (2000) Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol 20:3497–3509CrossRefPubMedGoogle Scholar
  48. Sathyanarayana UG, Toyooka S, Padar A et al (2003) Epigenetic inactivation of laminin-5-encoding genes in lung cancers. Clin Cancer Res 9:2665–2672PubMedGoogle Scholar
  49. Shapiro GI, Supko JG, Patterson A et al (2001) A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 7:1590–1599PubMedGoogle Scholar
  50. Shields JM, Pruitt K, McFall A et al (2000) Understanding Ras: ‘it ain't over ‘til it's over'. Trends Cell Biol 10:147–154CrossRefPubMedGoogle Scholar
  51. Shimizu E, Coxon A, Otterson GA et al (1994) RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 9:2441–2448PubMedGoogle Scholar
  52. Sklar MD (1988) The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 239:645–647PubMedGoogle Scholar
  53. Slebos RJ, Kibbelaar RE, Dalesio O et al (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561–565PubMedGoogle Scholar
  54. Soria JC, Lee HY, Lee JI et al (2002) Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8:1178–1184PubMedGoogle Scholar
  55. Sozzi G, Veronese ML, Negrini M et al (1996) The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85:17–26PubMedGoogle Scholar
  56. Sridhar SS, Seymour L, Shepherd FA (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4:397–406CrossRefPubMedGoogle Scholar
  57. Volm M, Drings P, Wodrich W et al (1993) Expression of oncoproteins in primary human non-small cell lung cancer and incidence of metastases. Clin Exp Metastasis 11:325–329CrossRefPubMedGoogle Scholar
  58. Watson JD, Crick FH (1953) Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 171:737–738PubMedGoogle Scholar
  59. Westra WH, Baas IO, Hruban RH et al (1996) K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res 56:2224–2228PubMedGoogle Scholar
  60. Wistuba II, Behrens C, Virmani AK et al (2000) High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 60:1949–1960PubMedGoogle Scholar
  61. Wistuba II, Gazdar AF, Minna JD (2001) Molecular genetics of small cell lung carcinoma. Semin Oncol 28:3–13CrossRefGoogle Scholar
  62. Wolff H, Saukkonen K, Anttila S et al (1998) Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58:4997–5001PubMedGoogle Scholar
  63. Wong JM, Collins K (2003) Telomere maintenance and disease. Lancet 362:983–988CrossRefPubMedGoogle Scholar
  64. Yashima K, Litzky LA, Kaiser L et al (1997) Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. Cancer Res 57:2373–2377PubMedGoogle Scholar
  65. Yu H, Spitz MR, Mistry J et al (1999) Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91:151–156CrossRefPubMedGoogle Scholar
  66. Zabarovsky ER, Lerman MI, Minna JD (2002) Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21:6915–6935CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Neil E. Martin
    • 1
  • Stephen M. Hahn
    • 1
  • W. Gillies McKenna
    • 1
  1. 1.Department of Radiation OncologyUniversity of Pennsylvania School of MedicinePhiladelphiaUSA

Personalised recommendations